A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to Compare the Efficacy and Safety of 60mg/kg Body Weight of Zemaira® Weekly I.V. Administration With Placebo Weekly I.V. Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
Latest Information Update: 21 Jan 2022
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Emphysema
- Focus Therapeutic Use
- Acronyms RAPID
- Sponsors CSL Behring
- 13 Sep 2018 According to a CSL Behring media release, results of the subgroup analysis of the RAPID trial programme will be presented at the 28th International Congress of the European Respiratory Society (ERS).
- 24 May 2017 Results of Post-Hoc Analysis of the RAPID/RAPID Extension Trial presented at the 113th International Conference of the American Thoracic Society
- 18 May 2016 Results (post hoc analysis, n = 177) assessing whether there were regional differences in treatment effect presented at the 112th International Conference of the American Thoracic Society.